BRIDGE-AI · BRaIn Disease monitoring throuGh the lifE span powered by Artificial Intelligence
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2025-11-01 → 2029-10-31
- Финансиране от ЕС
- 3 626 906 €
- Участници
- 18
- Схема
- HORIZON-TMA-MSCA-DN
Линиите свързват координатора с партньорите.
Накратко на български
Изкуственият интелект ще се използва за проследяване на развитието на мозъчни заболявания във времето, вместо само чрез единични снимки. Това помага за по-точно предвиждане на прогреса на болестта и реакцията на отделния пациент към лечението.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
BRIDGE-AI will train a new generation of innovative and entrepreneurial-oriented doctoral candidates (DCs) to move the state-of-the-art away from the snapshot interpretation of medical images by AI to a longitudinal follow-up and prediction of disease progression, covering a wide range of brain disorders across the entire lifespan. In an innovative departure of prevalent training models, each of BRIDGE-AI's DCs will be co-supervised by internationally leading experts from university research in biomedical image computing, world-renowned research hospitals, leading scanner manufacturers (Siemens, Philips) and medical imaging AI companies (incl. Bayer). Through this unique network, BRIDGE-AI will complete the entire circle from clinical needs to image acquisition, academic AI solution proposal, and commercial product for tracking disease progression and predicting treatment response in individual patients. Each of BRIDGE-AI's DCs will have a dedicated multidisciplinary and multisectoral thesis board, receiving input from industry, academia, and hospitals, and having access to large collections of clinical neuroimaging data, facilitating the evaluation of the true clinical relevance and impact of the proposed disease monitoring tools. Wide dissemination of the obtained methodological advances will be ensured by adopting a strong network-wide focus on open-source software.
Оригинален текст от CORDIS (на английски).
Участници
- AALTO KORKEAKOULUSAATIO SR · EspooКоординаторФинландия
- Athinoula A. Martinos Center for Biomedical Imaging · CharlestownСъединени щати
- Bayer Pharma AG · BerlinГермания
- CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS · LausanneШвейцария
- CONTEXTFLOW GMBH · WIENАвстрия
- DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV · BonnГермания
- ICOMETRIX NV · LeuvenБелгия
- MEDIZINISCHE UNIVERSITAET WIEN · WienАвстрия
- PHILIPS MEDICAL SYSTEMS NEDERLAND BV · BestНидерландия
- RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN · BonnГермания
- SIEMENS HEALTHINEERS INTERNATIONAL AG · ZURICHШвейцария
- TECHNISCHE UNIVERSITEIT EINDHOVEN · EindhovenНидерландия
- UNIVERSITAET BERN · BernШвейцария
- UNIVERSITAIR MEDISCH CENTRUM UTRECHT · UtrechtНидерландия
- UNIVERSITATSKLINIKUM BONN · BonnГермания
- UNIVERSITATSSPITAL BASEL · BaselШвейцария
- UNIVERSITE CATHOLIQUE DE LOUVAIN · LOUVAIN LA NEUVEБелгия
- UNIVERSITE DE LAUSANNE · LAUSANNEШвейцария
Връзки
Данни: CORDIS, © Европейски съюз